Overcoming these problems with its unique gene-silencing technology is OliX Pharmaceuticals, a clinical-stage/pure-play RNAi-therapeutics company that is changing the paradigm of RNAi-therapeutic ...

SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...

OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock ...

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. Olix will grant Eli ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

OliX Pharmaceuticals, a listed company on the KOSDAQ, has been designated as an investment warning stock due to a sharp rise in its stock price, and if the stock price rises further on the 18th ...